688302 海创药业
已收盘 11-19 15:00:01
资讯
新帖
简况
海创药业跌1.94% 2022年上市募资10.6亿元
中国经济网 · 16:16
海创药业跌1.94% 2022年上市募资10.6亿元
海创药业-U大跌 近半年2券商增持
智选洞察 · 13:42
海创药业-U大跌 近半年2券商增持
海创药业-U11月15日遭主力抛售218万元 环比增加458.97%
市场透视 · 11-15
海创药业-U11月15日遭主力抛售218万元 环比增加458.97%
海创药业-U大幅上涨 获主力净流入126万元
智选洞察 · 11-13
海创药业-U大幅上涨 获主力净流入126万元
海创药业:积极开展全球业务,广泛寻求商业权益授权合作机会
财经网 · 11-12
海创药业:积极开展全球业务,广泛寻求商业权益授权合作机会
海创药业-U大幅上涨 获主力净流入25万元
智选洞察 · 11-08
海创药业-U大幅上涨 获主力净流入25万元
海创药业-U大跌5.47% 3家券商给予增持建议
智选洞察 · 10-30
海创药业-U大跌5.47% 3家券商给予增持建议
海创药业(688302)10月28日主力资金净买入520.60万元
证券之星 · 10-29
海创药业(688302)10月28日主力资金净买入520.60万元
海创药业-U10月28日主力资金流入423万元 连续3日加仓
市场透视 · 10-28
海创药业-U10月28日主力资金流入423万元 连续3日加仓
海创药业(688302.SH)发布前三季度业绩,净亏损1.54亿元
智通财经 · 10-25
海创药业(688302.SH)发布前三季度业绩,净亏损1.54亿元
海创药业-U大幅上涨 获融资净买入428万元
智选洞察 · 10-24
海创药业-U大幅上涨 获融资净买入428万元
海创药业-U大幅上涨 获融资净买入935万元
智选洞察 · 10-21
海创药业-U大幅上涨 获融资净买入935万元
海创药业晚期乳腺癌产品临床试验获批 尚无同类PROTAC产品获批上市
红星新闻 · 10-15
海创药业晚期乳腺癌产品临床试验获批 尚无同类PROTAC产品获批上市
海创药业(688302.SH):HP568片开展用于治疗ER+/HER2-晚期乳腺癌的临床试验获批
智通财经 · 10-15
海创药业(688302.SH):HP568片开展用于治疗ER+/HER2-晚期乳腺癌的临床试验获批
海创药业:HP568片治疗ER+/HER2-晚期乳腺癌获批临床试验
证券之星 · 10-15
海创药业:HP568片治疗ER+/HER2-晚期乳腺癌获批临床试验
海创药业:获得《药物临床试验批准通知书》
每日经济新闻 · 10-15
海创药业:获得《药物临床试验批准通知书》
海创药业:股东盈创动力累计减持公司1%股份
红星新闻 · 10-15
海创药业:股东盈创动力累计减持公司1%股份
海创药业(688302)10月14日主力资金净卖出206.78万元
证券之星 · 10-15
海创药业(688302)10月14日主力资金净卖出206.78万元
10月14日海创药业发布公告,其股东减持99.02万股
证券之星 · 10-14
10月14日海创药业发布公告,其股东减持99.02万股
海创药业(688302.SH)股东盈创动力累计减持公司1%股份
智通财经 · 10-14
海创药业(688302.SH)股东盈创动力累计减持公司1%股份
加载更多
公司概况
公司名称:
海创药业股份有限公司
所属行业:
医药制造业
上市日期:
2022-04-12
主营业务:
海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。
发行价格:
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":35.38,"timestamp":1731999601000,"preClose":36.08,"halted":0,"volume":1357223,"delay":0,"floatShares":72724500,"shares":99015600,"eps":-2.1228,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.7,"latestTime":"11-19 15:00:01","open":36.28,"high":36.91,"low":34.05,"amount":47736000,"amplitude":0.0793,"askPrice":35.38,"askSize":20,"bidPrice":35.26,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-2.1228,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":36.08,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":39.69,"lowLimit":32.47,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":99015598,"pbRate":2.84,"roa":"--","roe":"--","epsLYR":-2.97,"committee":0.060241,"marketValue":3503000000,"floatMarketCap":2573000000,"peRate":-16.666666,"changeRate":-0.0194,"turnoverRate":0.0187,"status":1,"afterMarket":{"amount":0,"volume":0,"close":35.38,"buyVolume":0,"sellVolume":0,"time":1732001639464,"indexStatus":"已收盘 11-19 15:30:00","preClose":36.08}},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2484499169","title":"海创药业跌1.94% 2022年上市募资10.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484499169","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484499169?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:16","pubTimestamp":1732004160,"startTime":"0","endTime":"0","summary":" 海创药业首次公开发行股票募集资金总额为106,269.92万元,扣除发行费用后,募集资金净额为99,511.33万元。海创药业实际募资净额比原拟募资净额少150,884.55万元。海创药业于2022年4月7日披露的招股说明书显示,该公司拟募集资金250,395.88万元,分别用于研发生产基地建设项目、创新药研发项目、发展储备资金。 海创药业首次公开发行股票的发行费用总额为6,758.59万元,其中,承销及保荐费5,037.19万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-19/doc-incwqvpn6089017.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-19/doc-incwqvpn6089017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2484966283","title":"海创药业-U大跌 近半年2券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2484966283","media":"智选洞察","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484966283?lang=zh_cn&edition=full","pubTime":"2024-11-19 13:42","pubTimestamp":1731994956,"startTime":"0","endTime":"0","summary":"11月19日,海创药业-U股价大幅下跌,截至13点42分,海创药业-U下跌5.63%,报34.05元/股,创近1个月新低,成交2701万元,换手率1.05%,振幅7.93%。此外,数据统计显示,近半年内2家券商给予增持建议,1家券商给予买入建议。资金动向截止发稿,海创药业-U获得主力净流出60万元,其中超大单流出34万元,大单流出24万元。最新财报显示,今年三季报,海创药业-U实现营业收入10.97万元,同比减少-%,净利润为-1.54亿元,同比增长35.28%,基本每股收益为-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119134253abce4d1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119134253abce4d1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2483131715","title":"海创药业-U11月15日遭主力抛售218万元 环比增加458.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483131715","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483131715?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:20","pubTimestamp":1731655215,"startTime":"0","endTime":"0","summary":"11月15日, 海创药业-U股价跌3.85%,报收36.46元,成交金额3594万元,换手率1.32%,振幅4.93%,量比0.57。海创药业-U今日主力资金净流出218万元,上一交易日主力净流出39万元,今日环比增加458.97%。|11月15日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|三态股份|6.61%|#|岭南股份|6.59%|#|豆神教育|6.18%|#|福能东方|6.15%|#|福石控股|5.91%|#|传艺科技|5.61%|#|省广集团|4.73%|#|明月镜片|4.51%|#|国光电器|4.30%|#|博菲电气|4.15%|海创药业-U所在的化学制药行业,今日主力净流出7.90亿元,行业排名11/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115153309abc3acf3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115153309abc3acf3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2483043099","title":"海创药业-U大幅上涨 获主力净流入126万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483043099","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483043099?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:01","pubTimestamp":1731474092,"startTime":"0","endTime":"0","summary":"11月13日,海创药业-U股价大幅上涨,截至13点01分,海创药业-U上涨5.13%,报39.94元/股,成交6809万元,换手率2.43%,振幅8.08%。资金动向截止发稿,海创药业-U获得主力净流入126万元,其中超大单流入227万元,大单流出101万元。最新财报显示,今年三季报,海创药业-U实现营业收入10.97万元,同比减少-%,净利润为-1.54亿元,同比增长35.28%,基本每股收益为-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113130138a2327958&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113130138a2327958&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2482276727","title":"海创药业:积极开展全球业务,广泛寻求商业权益授权合作机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482276727","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482276727?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:39","pubTimestamp":1731400767,"startTime":"0","endTime":"0","summary":"11月12日,海创药业举办2024年第三季度业绩说明会。公司将根据监管机构的要求,组织团队将以最快的速度完成补充资料提交。公司也在积极和监管部门沟通,第一时间回复监管部门在评审过程当中的疑问。公司将根据项目进展及时披露相关信息。还有投资者询问,对于公司旗下的管线研发,有无拿一种海外出售的考虑。对此,管理层表示,公司积极开展全球业务和商务合作,广泛寻求商业权益授权合作机会,拓展国际化合作渠道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112164007a22fc624&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112164007a22fc624&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2481091161","title":"海创药业-U大幅上涨 获主力净流入25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481091161","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481091161?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:10","pubTimestamp":1731031849,"startTime":"0","endTime":"0","summary":"11月08日,海创药业-U股价大幅上涨,截至10点10分,海创药业-U上涨5.36%,报39.72元/股,成交1547万元,换手率0.56%,振幅5.36%。资金动向截止发稿,海创药业-U获得主力净流入25万元,其中超大单流入44万元,大单流出19万元。融资融券方面,海创药业-U11月06日获得融资净买入32万元,当日该股融资余额为4649万元,当较前一日增加0.71%,实现3连增;该股融券余额为19万元,融券余量为0.48万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108101157ababc192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108101157ababc192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2479246999","title":"海创药业-U大跌5.47% 3家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479246999","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479246999?lang=zh_cn&edition=full","pubTime":"2024-10-30 13:28","pubTimestamp":1730266118,"startTime":"0","endTime":"0","summary":"10月30日,海创药业-U股价大幅下跌,截至13点28分,海创药业-U下跌5.47%,报36.09元/股,成交3665万元,换手率1.35%,振幅5.37%。此外,数据统计显示,近半年内3家券商给予增持建议,1家券商给予买入建议。资金动向截止发稿,海创药业-U获得主力净流出458万元,其中超大单流出302万元,大单流出154万元。最新财报显示,今年三季报,海创药业-U实现营业收入10.97万元,同比减少-%,净利润为-1.54亿元,同比增长35.28%,基本每股收益为-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132955ab815b7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030132955ab815b7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2479493689","title":"海创药业(688302)10月28日主力资金净买入520.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479493689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479493689?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:20","pubTimestamp":1730161209,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月28日收盘,海创药业报收于39.18元,下跌2.63%,换手率3.02%,成交量2.19万手,成交额8637.91万元。近5日资金流向一览见下表:海创药业融资融券信息显示,融资方面,当日融资买入1174.52万元,融资偿还1066.33万元,融资净买入108.19万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2478064122","title":"海创药业-U10月28日主力资金流入423万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478064122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478064122?lang=zh_cn&edition=full","pubTime":"2024-10-28 15:18","pubTimestamp":1730099912,"startTime":"0","endTime":"0","summary":"10月28日, 海创药业-U股价跌2.63%,报收39.18元,成交金额8637万元,换手率3.02%,振幅4.08%,量比0.87。海创药业-U今日主力资金净流入423万元,连续3日净流入,上一交易日主力净流入822万元,今日环比减少48.54%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为38.46%,平均涨幅为2.07%。该股近5个交易日上涨7.34%,主力资金累计净流入1521万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出43万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028153132ab7a7d82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028153132ab7a7d82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2478640986","title":"海创药业(688302.SH)发布前三季度业绩,净亏损1.54亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478640986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478640986?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:49","pubTimestamp":1729856998,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)披露2024年第三季度报告,公司前三季度实现营收11万元;归母净利润亏损1.54亿元;扣非净利润亏损1.67亿元;基本每股收益-1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2477842549","title":"海创药业-U大幅上涨 获融资净买入428万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477842549","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477842549?lang=zh_cn&edition=full","pubTime":"2024-10-24 10:56","pubTimestamp":1729738574,"startTime":"0","endTime":"0","summary":"10月24日,海创药业-U股价大幅上涨,截至10点56分,海创药业-U上涨5.13%,报38.35元/股,成交5119万元,换手率1.87%,振幅5.35%。资金动向截止发稿,海创药业-U获得主力净流入292万元,其中超大单流出12万元,大单流入304万元。融资融券方面,海创药业-U10月22日获得融资净买入428万元,当日该股融资余额为4408万元,当较前一日增加9.77%,实现3连增;该股融券余额为10万元,融券余量为0.26万股,比上日减少73.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024105621a1e57483&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024105621a1e57483&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2477000450","title":"海创药业-U大幅上涨 获融资净买入935万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477000450","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477000450?lang=zh_cn&edition=full","pubTime":"2024-10-21 13:59","pubTimestamp":1729490384,"startTime":"0","endTime":"0","summary":"10月21日,海创药业-U股价大幅上涨,截至13点59分,海创药业-U上涨5.46%,报36.49元/股,成交6418万元,换手率2.57%。资金动向截止发稿,海创药业-U获得主力净流出716万元,其中超大单流出593万元,大单流出121万元。融资融券方面,海创药业-U10月18日获得融资净买入935万元,当日该股融资余额为3815万元,当较前一日增加32.51%;该股融券余额为31万元,融券余量为0.85万股,比上日增加1.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021140022a1e229a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021140022a1e229a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2475576950","title":"海创药业晚期乳腺癌产品临床试验获批 尚无同类PROTAC产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2475576950","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475576950?lang=zh_cn&edition=full","pubTime":"2024-10-15 18:50","pubTimestamp":1728989400,"startTime":"0","endTime":"0","summary":"经查询,截至本公告披露日,国内外无同类PROTAC产品获批上市。公告称,上述药品获得《药物临床试验批准通知书》事项对公司近期经营业绩不会产生重大影响。该药品获得《药物临床试验批准通知书》后,尚需开展临床试验研究并经国家药品监督管理局审评、审批通过后方可生产上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410151850529f449cc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410151850529f449cc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2475279545","title":"海创药业(688302.SH):HP568片开展用于治疗ER+/HER2-晚期乳腺癌的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2475279545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475279545?lang=zh_cn&edition=full","pubTime":"2024-10-15 18:11","pubTimestamp":1728987107,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业 发布公告,近日,公司收到中国国家药品监督管理局药品审评中心核准签发的《药物临床试验批准通知书》,同意HP568片开展用于治疗雌激素受体阳性和人表皮生长因子受体2阴性的晚期乳腺癌的临床试验。经查询,截至本公告披露日,国内外无同类PROTAC产品获批上市。体内小鼠模型中HP568能剂量依赖地抑制小鼠原位移植瘤生长,药物安全性良好。根据HP568的体内外研究结果,可以预期HP568是治疗 ER+/HER2-乳腺癌的有效药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","688302","BK1141","BK0239","03347","BK1576"],"gpt_icon":0},{"id":"2475527204","title":"海创药业:HP568片治疗ER+/HER2-晚期乳腺癌获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2475527204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475527204?lang=zh_cn&edition=full","pubTime":"2024-10-15 18:10","pubTimestamp":1728987000,"startTime":"0","endTime":"0","summary":"海创药业公告,公司收到国家药监局药品审评中心核准签发的《药物临床试验批准通知书》,同意HP568片开展用于治疗雌激素受体(Estrogen Receptor, ER)阳性和人表皮生长因子受体2(Human Epidermal Growth Factor Receptor, HER2)阴性的晚期乳腺癌(ER+/HER2-晚期乳腺癌)的临床试验。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500029588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0239","BK1583","688302","03347","BK1576"],"gpt_icon":0},{"id":"2475522903","title":"海创药业:获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2475522903","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475522903?lang=zh_cn&edition=full","pubTime":"2024-10-15 18:02","pubTimestamp":1728986539,"startTime":"0","endTime":"0","summary":"每经AI快讯,海创药业 10月15日晚间发布公告称,近日,海创药业股份有限公司收到中国国家药品监督管理局药品审评中心核准签发的《药物临床试验批准通知书》,同意HP568片开展用于治疗雌激素受体阳性和人表皮生长因子受体2阴性的晚期乳腺癌的临床试验。经查询,截至本公告披露日,国内外无同类PROTAC产品获批上市。2024年1至6月份,海创药业的营业收入构成为:材料占比100.0%。截至发稿,海创药业市值为32亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101518024295a9e8d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101518024295a9e8d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2475373202","title":"海创药业:股东盈创动力累计减持公司1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2475373202","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475373202?lang=zh_cn&edition=full","pubTime":"2024-10-15 10:04","pubTimestamp":1728957840,"startTime":"0","endTime":"0","summary":"本次权益变动后,盈创动力持有公司股份由956.3146万股减少至856.9996万股,占公司总股本比例由9.6582%减少至8.6552%。海创药业称,本次权益变动为持股5%以上非第一大股东的正常减持,不会导致公司控股股东、实际控制人发生变化。6月22日,海创药业公告显示,盈创动力计划通过集中竞价方式减持公司股份合计不超过99.015万股,合计减持比例不超过公司总股本的1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410151004269f42ef4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410151004269f42ef4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2475288329","title":"海创药业(688302)10月14日主力资金净卖出206.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475288329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475288329?lang=zh_cn&edition=full","pubTime":"2024-10-15 08:23","pubTimestamp":1728951795,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月14日收盘,海创药业报收于33.48元,下跌0.12%,换手率2.3%,成交量1.67万手,成交额5498.15万元。近5日资金流向一览见下表:海创药业融资融券信息显示,融资方面,当日融资买入414.15万元,融资偿还401.31万元,融资净买入12.84万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101500006896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2475366432","title":"10月14日海创药业发布公告,其股东减持99.02万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2475366432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475366432?lang=zh_cn&edition=full","pubTime":"2024-10-14 20:29","pubTimestamp":1728908945,"startTime":"0","endTime":"0","summary":"证券之星消息,10月14日海创药业发布公告《海创药业:关于持股5%以上股东减持计划时间届满暨权益变动达1%的公告》,其股东成都盈创动力创业投资有限公司于2024年7月15日至2024年10月14日间合计减持99.02万股,占公司目前总股本的1.0%,变动期间该股股价上涨24.93%,截止10月14日收盘报33.48元。股东增减持详情见下表:根据海创药业2024年中报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400028851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2475357971","title":"海创药业(688302.SH)股东盈创动力累计减持公司1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2475357971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475357971?lang=zh_cn&edition=full","pubTime":"2024-10-14 19:16","pubTimestamp":1728904586,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)发布公告,公司于近日收到股东盈创动力出具的《关于股份减持计划时间届满暨减持结果的告知函》,截至2024年10月14日,本次减持计划时间区间届满。本次减持计划实施期间,盈创动力累计减持公司股份99.02万股,占公司总股本的比例为1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":-0.0742},{"period":"1month","weight":0.0428},{"period":"3month","weight":0.4149},{"period":"6month","weight":0.1923},{"period":"1year","weight":-0.232},{"period":"ytd","weight":-0.3071}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"18383股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":" 海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台,以开发具有重大临床需求的Best-in-class(同类最佳)、First-in-class(国际首创)药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局,重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台,形成了较强的研发优势和丰富的技术储备。","serverTime":1732009203871,"listedPrice":42.92,"stockholders":"3956人(较上一季度增加14.80%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}